why choose us

First received: May 09, 2023

Clinical Trial: A Combination Study of CAR-T Therapy in r/r B-NHL

Study Status: Completed

Recruit Status: RECRUITING

Condition: Diffuse Large B Cell Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase II Study of BTKi+Radiotherapy±Chemotherapy Bridging Before Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T) in Combination With BTKi±PD-1 Inhibitor Maintenance Therapy for Relapsed/

Brief Summary: In registry studies of CAR-T products that have been marketed globally, patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) have been enrolled to receive CAR-T infusion in combination with tyrosine kinase inhibitors (BTKi) or immune checkpoint inhibitors (PD-1 or PD-L1 antibodies), with objective remission rate (ORR) for CAR-T in combination with BTKi ranging from 83.3%-100% and complete remission rate (CRR) were 33.3-75%.The ORRs for objective remission rates for CAR-T…

Read more